Y-mAbs Therapeutics Competitors and Similar CompaniesClear all
Y-mAbs Therapeutics's competitors and similar companies include Thor Medical, Design Therapeutics, Molecular Partners and Prevail Therapeutics.
 Y-mAbs Therapeutics Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets. |  Thor Medical Thor Medical (formerly known as Nordic Nanovector) is a biopharmaceutical company that focuses on the development and commercialisation of novel targeted therapeutics in haematology and oncology. |  Design Therapeutics Design Therapeutics is a biopharmaceutical company engaged the research and development of small-molecule gene targeted chimera therapeutic candidates. |  Molecular Partners Molecular Partners is a company that develops biopharmaceutical products for serious diseases. |  Prevail Therapeutics Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease. | |
Founding Date | Founding Date 2014 | Founding Date 2009 | Founding Date 2017 | Founding Date 2004 | Founding Date 2017 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations New York, US HQ Copenhagen, DK Nutley, US | Locations Oslo, NO HQ Zug, CH Shrewsbury, GB | Locations Carlsbad, US HQ | Locations Zürich-Schlieren, CH HQ Cambridge, US Concord, US | Locations New York, US HQ |
Employees | Employees 3239% increase | Employees 3716% decrease | Employees 54 | Employees 158 | Employees 489% increase |
Valuation ($) | Valuation ($) 657 m | Valuation ($) 131.4 m | Valuation ($) 313.1 m | Valuation ($) N/A | Valuation ($) 787.7 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $87.7m (FY, 2024) | Revenue (est.) kr439k (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods $15m (FY, 2024) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $72.7m (FY, 2024) | Gross profit kr4.3m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income ($29.7m) (FY, 2024) | Net income (kr58m) (FY, 2025) | Net income ($69.8m) (FY, 2025) | Net income (CHF61.7m) (FY, 2025) | Net income ($63.2m) (FY, 2019) |
Funding | |||||
Total funding raised | Total funding raised $ 80m | Total funding raised N/A | Total funding raised $ 45m | Total funding raised N/A | Total funding raised $ 125m |
For sources of this data, please see the company profile
View Company Profiles
Thor Medical
HQ
Oslo, NO
Employees
37↓ 16% decrease
Thor Medical (formerly known as Nordic Nanovector) is a biopharmaceutical company that focuses on the development and commercialisation of novel targeted therapeutics in haematology and oncology.
View companyDesign Therapeutics
HQ
Carlsbad, US
Employees
54
Design Therapeutics is a biopharmaceutical company engaged the research and development of small-molecule gene targeted chimera therapeutic candidates.
View companyMolecular Partners
HQ
Zürich-Schlieren, CH
Employees
158
Molecular Partners is a company that develops biopharmaceutical products for serious diseases.
View companyPrevail Therapeutics
HQ
New York, US
Employees
48↑ 9% increase
Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease.
View company